HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

6- (2- aminocyclohexylamino)- 4- (5,6- dimethylpyridin- 2- ylamino)pyridazine- 3- carboxylic acid amide

inhibits spleen tyrosine kinase; structure in first source

Also Known As:

RO9021

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Aminopyridines: 77
    - 6-(2-aminocyclohexylamino)-4-(5,6-dimethylpyridin-2-ylamino)pyridazine-3-carboxylic acid amide: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Aminopyridines: 77
      - 6-(2-aminocyclohexylamino)-4-(5,6-dimethylpyridin-2-ylamino)pyridazine-3-carboxylic acid amide: 2
  - Pyridazines: 11
    - 6-(2-aminocyclohexylamino)-4-(5,6-dimethylpyridin-2-ylamino)pyridazine-3-carboxylic acid amide: 2

Experts

1.	Ding, Changhai: 1 article (03/2022)
2.	Tang, Su'an: 1 article (03/2022)
3.	Yu, Qinghong: 1 article (03/2022)
4.	DeMartino, Julie: 1 article (10/2013)
5.	Hermann, Johannes: 1 article (10/2013)
6.	Hsu, Jonathan: 1 article (10/2013)
7.	Hu, Dong-Qing: 1 article (10/2013)
8.	Kim, Yong: 1 article (10/2013)
9.	Liao, Cheng: 1 article (10/2013)
10.	Lucas, Matthew: 1 article (10/2013)

Related Diseases

1.	Autoimmune Diseases (Autoimmune Disease) 10/04/2013 - "Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy." 03/01/2022 - "The search terms used were SYK inhibitors, R406, fostamatinib (R788), P505-15 (PRT062607), entospletinib (GS-9973), R112, lanraplenib (GS-9876), cerdulatinib, R343, BAY-61-3606, GSK compound 143 (GSK143), R211, SKI-G-618, SKI-O-85, ER-27319, YM193306, RO9021 in conjunction with autoimmune disease using electronic databases including PubMed, EMBASE, MEDLINE and Google Scholar. "
2.	Inflammation (Inflammations) 10/04/2013 - "RO9021 could serve as a starting point for the development of selective SYK inhibitors for the treatment of inflammation-related and autoimmune-related disorders."
3.	Arthritis (Polyarthritis) 10/04/2013 - "Finally, oral administration of RO9021 inhibited arthritis progression in the mCIA model, with observable pharmacokinetics (PK)-pharmacodynamic (PD) correlation. "

Related Drugs and Biologics

1.	Syk Kinase
2.	GSK143
3.	4- (3- (2H- 1,2,3- triazol- 2- yl)phenylamino)- 2- (2- aminocyclohexylamino)pyrimidine- 5- carboxamide
4.	fostamatinib
5.	2- (7- (3,4- dimethoxyphenyl)imidazo(1,2- c)pyrimidin- 5- ylamino)nicotinamide
6.	ER 27319
7.	4- (cyclopropylamino)- 2- ((4- (4- (ethylsulfonyl)piperazin- 1- yl)phenyl)amino)pyrimidine- 5- carboxamide
8.	6- (1H- indazol- 6- yl)- N- (4- morpholinophenyl)imidazo(1,2- a)pyrazin- 8- amine

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration